Type 1 Diabetes Mellitus Diagnosed during Follow-up of Gestational Diabetes Mellitus in the Early Postpartum Period

Toshiyuki Ikeoka¹, Ayaka Sako¹, Genpei Kuriya¹, Hiroshi Yamashita², Ichiro Yasuhi², Ichiro Horie³, Takao Ando³, Norio Abiru³ and Atsushi Kawakami³

Abstract:
A 27-year-old woman with a history of gestational diabetes mellitus (GDM) developed type 1 diabetes mellitus (T1D) in the early postpartum period. Women with a history of GDM are at an increased risk of developing T1D, which is rarer than type 2 diabetes mellitus. A postpartum follow-up 75-g oral glucose tolerance test and the measurement of glutamic acid decarboxylase autoantibodies aided in the early detection of T1D in this patient. Careful attention should be paid to women with a history of GDM who exhibit clinical features suggestive of future development of T1D.

Key words: gestational diabetes mellitus, type 1 diabetes mellitus, slowly progressive type 1 diabetes mellitus, postpartum

(Intern Med 57: 3413-3418, 2018) (DOI: 10.2169/internalmedicine.1188-18)

Introduction
Gestational diabetes mellitus (GDM) is defined by the onset or first recognition of abnormal glucose tolerance during pregnancy that is less severe than overt diabetes mellitus (1). In a systematic review and meta-analysis, women with a history of GDM had at least a seven-fold increased risk of developing type 2 diabetes mellitus (T2D) during the postpartum period compared to those who were normoglycemic during their pregnancies (2). Women with GDM are predisposed to developing type 1 diabetes mellitus (T1D) in the postpartum period if they have pancreatic beta-cell autoantibodies (3-5).

The prevalence of glutamic acid decarboxylase autoantibodies (GADA) in women with GDM in a previous or current pregnancy is reported to be 0-9.5% (3-15). T1D is a chronic autoimmune disease, and the pre-diabetic stage can exist concurrently with immunologic abnormalities (16). Pregnant women with an abnormal glucose tolerance can be diagnosed with GDM even if they are in the pre-diabetic stage of T1D, which may result in patients with T1D being overlooked. The early diagnosis and insulin therapy for T1D help prevent acute complications, such as diabetic ketoacidosis.

We herein report a patient with T1D diagnosed using a 75-g oral glucose tolerance test (OGTT) during follow-up of GDM in the postpartum period.

Case Report
A 27-year-old woman, gravida 2 para 0, with a family history of diabetes mellitus was referred to our hospital’s obstetrics and gynecology department for GDM management at 27 weeks’ gestation. She was diagnosed with GDM after the first 75-g OGTT based on plasma glucose levels of 73 mg/dL, 193 mg/dL, and 173 mg/dL at fasting, 1-hour, and 2-hour post-glucose load, respectively. She was prescribed nutritional therapy of 1,900 kcal per day, consisting of three small-to-moderate sized meals and three snacks and

¹Department of Endocrinology and Metabolism, National Hospital Organization Nagasaki Medical Center, Japan, ²Department of Obstetrics and Gynecology, National Hospital Organization Nagasaki Medical Center, Japan and ³Department of Endocrinology and Metabolism, Nagasaki University Graduate School of Biomedical Sciences, Japan
Received: March 14, 2018; Accepted: May 6, 2018; Advance Publication by J-STAGE: August 10, 2018
Correspondence to Dr. Toshiyuki Ikeoka, toshiyukiikeoka@hotmail.co.jp
was instructed to perform frequent daily blood glucose self-monitoring. However, her postprandial blood glucose levels remained in the 140-180 mg/dL range, despite nutritional therapy. The neutral protamine Hagedorn was started at 10 units before breakfast. Her insulin doses were titrated according to the fasting and postprandial blood glucose levels. Insulin aspart was added at 29 weeks’ gestation. Her total insulin dose was 38 units per day at 34 weeks’ gestation. She delivered a male infant, weighing 3,220 g at 40 weeks’ gestation by vaginal delivery. The infant’s 1- and 5-minute Apgar scores were 8 and 9, respectively. At her six-week postpartum follow-up visit, a second 75-g OGTT was performed. The 2-hour plasma glucose level was 258 mg/dL, indicating the likelihood of overt diabetes, although her hemoglobin A1c (HbA1c) was only 5.7%, and her glycated albumin was 14.1%. A third 75-g OGTT at 4 months postpartum showed plasma glucose levels of 131 mg/dL, 356 mg/dL, and 453 mg/dL on fasting, 1-hour, and 2-hour post-glucose loads, respectively. She also had an elevated HbA1c of 6.7%, and a glycated albumin of 22.5%. Her urinary ketone bodies were negative. Based on these findings, she was diagnosed with overt diabetes and was referred to our department for further testing and treatment. She denied polydipsia, polyuria, and fatigue. After the third OGTT, she had a positive pregnancy test. Intensive insulin therapy was started, but unfortunately, she miscarried after one week. The GADA result was reported to be 57.1 U/mL at 6 months postpartum. Based on her clinical course and GADA-positive status, she was diagnosed with T1D and admitted for further work-up.

Her body mass index was 16.9 kg/m². Her physical examination was unremarkable. The laboratory data measured at admission are shown in Table 1 and indicate normal liver, kidney, and thyroid functions. Her tests were negative for anti-thyroid antibodies, including thyrotropin receptor antibodies, anti-thyroglobulin antibodies, and anti-thyroid peroxidase antibodies. She had elevated levels of anti-insulinoma antigen 2 antibody (IA2A), which was measured at admission. An intravenous glucagon stimulation test was performed, with blood samples for glucose and C-peptide taken at baseline and at 6 minutes. Her plasma glucose levels were 75 and 103 mg/dL at baseline and 6 minutes, respectively, and the corresponding serum C-peptide levels were 0.5 and 1.2 ng/mL at baseline and at 6 minutes, respectively. The urinary C-peptide excretion was 13.3 μg/day, which suggested that she was in an insulin-dependent state. A continuous subcutaneous insulin infusion (CSII) was started at a dose of 8 units per day. She was discharged with CSII and remained in good glycemic control. She did not exhibit signs of diabetic neuropathy, retinopathy, or nephropathy. We retrospectively measured levels of GADA and IA2A in a stored blood sample at the second 75-g OGTT. The levels of GADA and IA2A were 75 and 103 mg/dL at baseline and 6 minutes, respectively, and the corresponding serum C-peptide levels were 0.5 and 1.2 ng/mL at baseline and at 6 minutes, respectively. The urinary C-peptide excretion was 13.3 μg/day, which suggested that she was in an insulin-dependent state. A continuous subcutaneous insulin infusion (CSII) was started at a dose of 8 units per day. She was discharged with CSII and remained in good glycemic control. She did not exhibit signs of diabetic neuropathy, retinopathy, or nephropathy. We retrospectively measured levels of GADA and IA2A in a stored blood sample at the second 75-g OGTT. The levels of GADA and IA2A were 75 and 103 mg/dL at baseline and 6 minutes, respectively. The urinary C-peptide excretion was 13.3 μg/day, which suggested that she was in an insulin-dependent state. A continuous subcutaneous insulin infusion (CSII) was started at a dose of 8 units per day. She was discharged with CSII and remained in good glycemic control. She did not exhibit signs of diabetic neuropathy, retinopathy, or nephropathy. We retrospectively measured levels of GADA and IA2A in a stored blood sample at the second 75-g OGTT. The levels of GADA and IA2A were 75 and 103 mg/dL at baseline and 6 minutes, respectively. The urinary C-peptide excretion was 13.3 μg/day, which suggested that she was in an insulin-dependent state.

### Table 1. Laboratory Results on Admission.

| Test                        | Reference | Blood Count |
|-----------------------------|-----------|-------------|
| Glucose (mg/dL)             | 78        | White blood cell (µL) 5,100 | 3,300-8,600 |
| Hemoglobin A1c (%)          | 5.8       | Red blood cell (x10⁹ µL) | 386 | 386-492 |
| Urinary C-peptide (µg/day)  | 13.3      | Hemoglobin (g/dL) | 11.7 | 11.6-14.8 |
| IA-2 antibody (U/mL)        | 8.2       | Platelet (x10⁹ µL) | 26.6 | 15.8-34.8 |
| Insulin autoantibody (µU/mL)| 2,080     | Blood Chemistry |
| Urinary ketone bodies       | -         | Aspartate aminotransferase (U/L) 12 | 13-30 |
| Thyroid                     |           | Alanine aminotransferase (U/L) 6 | 7-23 |
| Free thyroxine (ng/dL)      | 0.87      | Lactate dehydrogenase (U/L) | 117 | 124-222 |
| Thyroid stimulating hormone (mU/mL) | 1.143 | ̵13.5-4.940 |
| Thryotropin receptor antibodies (IU/mL) | 0.5 | <2 |
| Thyroglobulin antibodies (IU/mL) | 11 | <28 |
| Thyroid peroxidase antibodies (IU/mL) | 7 | <16 |

**IA-2**: anti-insulinoma antigen 2

Discussion

We encountered a woman with a history of GDM who was subsequently diagnosed with T1D in the early postpartum period, based on the results of a 75-g OGTT at 4 months postpartum. In this case, her relatively young age and parity, insulin treatment during pregnancy, and pancreatic beta-cell autoantibodies positivity were the factors possibly associated with the development of T1D. Jarvela et al. reported that age younger than 30 years, insulin treatment for GDM, islet cell antibody positivity, and the presence of
GADAs were all associated with an increased risk of developing T1D (4). Our patient exhibited findings that were consistent with three of the above-mentioned characteristics. Fuchtenbusch et al. reported that the risk of developing T1D increased with the number of antibodies present at delivery (3). Our patient was positive for both GADA and IA2A, which indicates that the odds ratio for developing T1D postpartum would be at least 49.6, according to that study’s findings (3). Fuchtenbusch et al. also reported that women with one or more pregnancies before the index pregnancy had a higher risk of developing T1D in the postpartum period than women after their first pregnancy (3). In this case, the patient had had one pregnancy prior to the index pregnancy. Taken together, the above characteristics indicate that our patient was predisposed to developing T1D postpartum.

A 75-g OGTT is recommended at the 4- or 6- to 12-week postpartum visit in women with a history of GDM (17-19). In this patient, the OGTT was performed at the 6-week postpartum visit. In our previous study, only 6 out of 169 (3.6%) Japanese women with GDM showed patterns consistent with diabetes at their 6- to 8-week postpartum 75-g OGTTs (20), indicating the low prevalence of diabetic patterns at 6 to 8 weeks postpartum. Lobner et al. reported that almost 50% of women with pancreatic beta-cell autoantibodies developed diabetes within 6 months of delivery, which was relatively rapid compared to those without autoantibodies (21). Therefore, careful attention should be paid to the possibility of developing T1D in women with abnormal 75-g OGTTs in the early postpartum period.

Lundberg et al. reported that, compared to women who were GADA-negative, women who were GADA-positive had significantly increased 0- and 2-hour plasma glucose levels and decreased serum insulin levels at 0 and 30 minutes on the postpartum 75-g OGTT (15). In our patient, the magnitude of the rise in the 2-hour plasma glucose levels on the OGTT was greater than that of the plasma glucose levels at 0 hour on the first, second, and third OGTTs. High-intensity breastfeeding improves glucose metabolism and insulin sensitivity (22, 23). The infant in this case was primarily being breastfed around the time of the second 75-g OGTT but had transitioned to primarily formula feeding around the time of the third 75-g OGTT, which may have contributed to the deterioration of glycemic control from the second to the third OGTT. The measurement of plasma glucose levels at 2 hours on the OGTT may provide an opportunity for an early diagnosis of T1D.

Comparing the first 75-g OGTT to the second 75-g OGTT, the insulinogenic index (24, 25) decreased from 0.13 to 0.07, and the homeostasis model assessment of the beta-cell function (26) decreased from 154.8 to 34.2. In contrast, the homeostasis model assessment of insulin resistance (26) increased from 0.78 to 1.00, the Matsuda index (27) de-
Glucagon stimulation test results and the urinary C-peptide cannot be excluded in this patient. Based on the intravenous OGTT. However, the possibility of acute-onset T1D (31) suspected to have occurred before the second postpartum period. Nine of those 12 patients developed fulminant T1D (29). Our patient did not present with ketosis or ketosis without the requirement of insulin for at least three months from the onset of diabetes, although GADA was positive.

We searched PubMed and the Japanese Igaku-Chuo-Zassi database using a combination of the key words, “slowly progressive type 1 diabetes mellitus” and “gestational diabetes mellitus”. The characteristics of five patients, including the present patient, were consistent with SPIDDM following a diagnosis of GDM (Table 2) (32-34). The mean age of these patients was 34 years, and the mean BMI was 19.5 kg/m², which was relatively low. This low BMI may provide clues for identifying women who are GADA-positive, since these women have been diagnosed with GDM and are known to be leaner than women who are GADA-negative with GDM (8). All five patients were prescribed insulin during pregnancy. Each patient had characteristics that predisposed them to developing T1D. Patients 1 and 3 had longer time-spans between the diagnoses of GDM and SPIDDM and higher HbA1c levels and lower serum C-peptide levels than the other patients. These two patients were insulin-dependent, according to their fasting serum C-peptide levels, possibly due to delayed insulin therapy resulting in rapid beta-cell destruction. Insulin therapy has been known to preserve the beta-cell function in patients diagnosed with SPIDDM (35). Patients 2 and 4 were diagnosed with SPIDDM shortly after the diagnosis of GDM during pregnancy. The blood glucose levels are frequently measured in women whose pregnancies are complicated by GDM. This allows for the early diagnosis of SPIDDM and prevents the further deterioration of glycemic control.

In conclusion, we encountered a patient with an early postpartum diagnosis of T1D after a pregnancy complicated by GDM. T1D can be overlooked in women diagnosed with GDM. Therefore, these patients will need not only fasting plasma glucose and HbA1c tests but also OGTTs in the postpartum period, which may be more helpful for identifying T1D than measuring only fasting plasma glucose and HbA1c. Glycemic control deteriorates more rapidly in those who have pancreatic beta-cell autoantibodies, including GADA, although the prevalence of GADA is low. Women with GDM who have clinical features suggestive of future T1D should have their GADA levels measured for the early detection of T1D.

Table 2. Case Reports of SPIDDM after Diagnosis of GDM.

| Case | Age | BMI (kg/m²) | Family history | GADA | HbA1c (%) | F-CPR (ng/mL) | Insulin | Duration (months) | Reference |
|------|-----|-------------|----------------|------|-----------|--------------|---------|------------------|-----------|
| 1    | 36  | 21.6        | -              | +    | 9.9       | 0.33         | +       | 120              | (32)      |
| 2    | 34  | 18.9        | +              | +    | 6.7       | 0.59         | +       | 1                | (33)      |
| 3    | 42  | 18.2        | +              | +    | 8.9       | 0.23         | +       | 72               | (34)      |
| 4    | 31  | 22.1        | +              | +    | 5.5       | 0.62         | +       | 1                | (34)      |
| 5    | 27  | 16.9        | +              | +    | 6.7       | 0.5          | +       | 9                | present case |

SPIDDM: slowly progressive type 1 diabetes mellitus, GDM: gestational diabetes mellitus. Age: age at diagnosis of SPIDDM. BMI: non-pregnant body mass index (except for case 4 which was measured at 28 weeks’ gestation). Family history: family history of diabetes mellitus. F-CPR: non-pregnant fasting serum C-peptide, GADA: anti-glutamic acid decarboxylase antibody, HbA1c: hemoglobin A1c measured at the time of SPIDDM diagnosis, Insulin: insulin treatment during pregnancy, Duration: timespan between the diagnosis of GDM and the diagnosis of SPIDDM.
The authors state that they have no Conflict of Interest (COI).

References

1. Metzger BE, Gabbe SG, Persson B, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 33: 676-682, 2010.

2. Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 373: 1773-1779, 2009.

3. Fuchtenbusch M, Ferber K, Standl E, Ziegler AG. Prediction of type 1 diabetes postpartum in patients with gestational diabetes mellitus by combined islet cell autoantibody screening: a prospective multicenter study. Diabetes 46: 1459-1467, 1997.

4. Jarvela IV, Juutinen J, Koskela P, et al. Gestational diabetes identifies women at risk for permanent type 1 and type 2 diabetes in fertile age: predictive role of autoantibodies. Diabetes Care 29: 607-612, 2006.

5. Nilsson C, Ursing D, Torn C, Aberg A, Landin-Olsson M. Presence of GAD antibodies during gestational diabetes mellitus predicts type 1 diabetes. Diabetes Care 30: 1968-1971, 2007.

6. Dozio N, Beretta A, Belloni C, et al. Low prevalence of islet autoantibodies in patients with gestational diabetes mellitus. Diabetes Care 20: 81-83, 1997.

7. Mitchell ML, Hermos RJ, Larson CA, Palomaki GE, Haddow JE. Prevalence of GAD autoantibodies in women with gestational diabetes: a retrospective analysis. Diabetes Care 23: 1705-1706, 2000.

8. Kousta E, Lawrence NJ, Anyaoku V, Johnston DG, McCarthy MI. Prevalence and features of pancreatic islet cell autoimmunity in women with gestational diabetes from different ethnic groups. Br J Obstet Gynaecol 108: 716-720, 2001.

9. Lapolla A, Fedele D, Pedini B, et al. Low frequency of autoantibodies to islet cell, glutamic acid decarboxylase, and second-islet antigen in patients with gestational diabetes mellitus: a follow-up study. Ann N Y Acad Sci 958: 263-266, 2002.

10. Bo S, Menato G, Pinach S, et al. Clinical characteristics and outcome of pregnancy in women with gestational hyperglycaemia with and without antibodies to beta-cell antigens. Diabet Med 20: 64-68, 2003.

11. Ferraz TB, Motta RS, Capibaribe DM, et al. Prevalence of GAD autoantibodies in Brazilian women with previous gestational diabetes. Diabetes Res Clin Pract 78: 141-142, 2007.

12. Murgia C, Ortu M, Portoghese E, et al. Autoimmunity in gestational diabetes mellitus in Sardinia: a preliminary case-control report. Reprod Biol Endocrinol 6: 24, 2008.

13. Yu SH, Park S, Kim HS, et al. The prevalence of GAD antibodies in Korean women with gestational diabetes mellitus and their clinical characteristics during and after pregnancy. Diabetes Metab Res Rev 25: 329-334, 2009.

14. Papadopoulos A, Lynch KF, Anderberg E, et al. HLA-DQB1 genotypes and islet cell autoantibodies against GAD65 and IA-2 in relation to development of diabetes postpartum in women with gestational diabetes mellitus. Diabetes Res Clin Pract 95: 260-264, 2012.

15. Lundberg TP, Hojlund K, Snogdal LS, Jensen DM. Glutamic acid decarboxylase autoantibody-positivity post-partum is associated with impaired beta-cell function in women with gestational diabetes mellitus. Diabet Med 32: 198-205, 2015.

16. Eisenbarth GS. Type 1 diabetes mellitus. A chronic autoimmune disease. N Engl J Med 314: 1360-1368, 1986.

17. Metzger BE, Buchanan TA, Coustan DR, et al. Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 30: S251-S260, 2007.

18. Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 98: 4227-4249, 2013.

19. American Diabetes Association. 13. Management of diabetes in pregnancy. Diabetes Care 40 (Suppl 1): S114-S119, 2017.

20. Kugishima Y, Yasuhi I, Yamashita H, et al. Risk factors associated with abnormal glucose tolerance in the early postpartum period among Japanese women with gestational diabetes. Int J Gynaecol Obstet 129: 42-45, 2015.

21. Lobner K, Knopf A, Baumgarten A, et al. Predictors of postpartum diabetes in women with gestational diabetes mellitus. Diabetes 55: 792-797, 2006.

22. Gunderson EP, Hedderson MM, Chiang V, et al. Lactation intensity and postpartum maternal glucose tolerance and insulin resistance in women with recent GDM: the SWIFT cohort. Diabetases 35: 50-56, 2012.

23. Yasuhi I, Soda T, Yamashita H, et al. The effect of high-intensity breastfeeding on postpartum glucose tolerance in women with recent gestational diabetes. Int Breastfeed J 12: 32, 2017.

24. Phillips DI, Clark PM, Hales CN, Osmond C. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 11: 286-292, 1994.

25. Matsumoto K, Miyake S, Yano M, et al. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care 20: 1562-1568, 1997.

26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.

27. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462-1470, 1999.

28. Renmakaran R, Qi Y, Goran MI, Hamilton JK. Evaluation of proposed oral disposition index measures in relation to the actual disposition index. Diabet Med 26: 1198-1203, 2009.

29. Kawasaki E, Shimizu I, Hanafusa T, et al. Nationwide survey on the prevalence of type 1 diabetes associated with pregnancy. Tounyoubyou to Ninshin (Diabetes & Pregnancy) 6: 104-107, 2006 (in Japanese).

30. Tanaka S, Ohmori M, Arawa T, et al. Diagnostic criteria for slowly progressive insulin-dependent (type 1) diabetes mellitus (SPIDDM) (2012): report by the committee on slowly progressive insulin-dependent (type 1) diabetes mellitus of the Japan diabetes society. Diabetology International 6: 1-7, 2015.

31. Kawasaki E, Maruyama T, Imagawa A, et al. Diagnostic criteria for acute-onset type 1 diabetes mellitus (2012): Report of the Committee of Japan Diabetes Society on the Research of Fulminating and Acute-onset Type 1 Diabetes Mellitus. J Diabetes Invest 5: 115-118, 2014.

32. Horie I, Kawasaki E, Shimomura A, et al. Emergence of anti-islet autoantibodies in Japanese patients with type 1 diabetes. Endocr J 57: 623-628, 2010.

33. Ide S, Minabe M, Kawahara K, Muraoka M, Takagi K. A case of slowly progressive insulin dependent diabetes mellitus during pregnancy. Nihon Sanka Fujinka Gakkai Tokyo Chihoubukaiishi (Tokyo Journal of Obstetrics and Gynecology) 60: 76-80, 2011 (in Japanese).

34. Ichimura Y, Yanagisawa K, Kambara M, et al. Two cases of slowly progressive type 1 diabetes mellitus diagnosed after being fertile age: Report of the Committee of Japan Diabetes Society on the Research of Fulminating and Acute-onset Type 1 Diabetes Mellitus (Diabetes & Pregnancy) (Suppl 1): S114-S119, 2017 (in Japanese).

35. Maruyama T, Tanaka S, Shimada A, et al. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. J Clin Endocrinol Metab 93: 2115-2121, 2008.
